卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的疗效及对患者血清肿瘤标志物、血管内皮生长因子和基质金属蛋白酶-9的影响  

Efficacy of camrelizumab combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer and its effect on serum tumor markers,vascular endothelial growth factor and matrix metalloproteinase-9

作　　者：泮卫红 朱文娟 班晓辉 程闪闪 PAN Weihong;ZHU Wenjuan;BAN Xiaohui;CHENG Shanshan(Second Ward of Oncology,Bashan Wanjie Hospital,Zibo,Shandong,255213,China)

机构地区：[1]淄博岜山万杰医院肿瘤科二病区,山东淄博255213

出　　处：《当代医学》2024年第3期40-43,共4页Contemporary Medicine

摘　　要：目的探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者血清肿瘤标志物、血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)的影响。方法选取2019年1月至2021年12月淄博岜山万杰医院肿瘤科收治的62例晚期NSCLC患者作为研究对象,随机分为观察组与对照组,每组31例。对照组给予依托泊苷联合顺铂化疗方案,观察组在对照组基础上联合卡瑞利珠单抗治疗。比较两组临床疗效、治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原72-4(CA72-4)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、VEGF和MMP-9水平。结果观察组治疗总有效率为54.84%,高于对照组的29.03%,差异有统计学意义(P<0.05);治疗后,两组CEA、CA72-4和CYFRA21-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组VEGF、MMP-9水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论卡瑞利珠单抗联合化疗可有效提高晚期NSCLC患者近期疗效,降低血清肿瘤标志物水平,抑制VEGF和MMP-9表达,有效防止肿瘤转移和侵袭,效果优于单纯化疗。Objective To investigate the efficacy of camrelizumab combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC)and its effect on serum tumor markers,vascular endothelial growth factor(VEGF)and matrix metalloproteinase-9(MMP-9).Methods A total of 62 patients with advanced NSCLC admitted to the Oncology department of Bashan Wanjie Hospital of Zibo from Jan-uary 2019 to December 2021 were selected as the research subjects,and they were randomly divided into the observation group and the control group,with 31 cases in each group.The control group was treated with etoposide combined with cisplatin chemotherapy,and the observation group was treated with camrelizumab on the basis of the control group.The clinical efficacy,the serum tumor markers(carcino-embryonic antigen[CEA],carbohydrate antigen72-4[CA72-4]and cyto-keratin 19 fragment antigen 21-1[CYFRA21-1]),vascular endothelial growth factor(VEGF)and ma-trix metalloproteinase-9(MMP-9)before and after treatment were compared between the two groups.Results The total effective rate in the observa-tion group was 54.84%,which was higher than 29.03%in the control group,and the difference was statistically significant(P<0.05);after treatment,the levels of CEA,CA72-4,CyFRA21-1,VEGF and MMP-9 of the two groups were lower than those before treatment,and the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of VEGF and MMP-9 of the two groups were lower than those before treatment,and the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Camrelizumab combined with chemotherapy can effectively improve the short-term efficacy of advanced NSCLC patients,reduce the level of serum tumor markers,inhibit the expression of VEGF and MMP-9,and effectively prevent tumor me-tastasis and invasion.The effect is better than that of chemotherapy alone.

关 键 词：卡瑞利珠单抗 非小细胞肺癌 血清肿瘤标志物 化疗 血管内皮生长因子 基质金属蛋白酶-9 

分 类 号：R734.2[医药卫生—肿瘤]